BDC-1001

· Bolt Biotherapeutics, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for BDC-1001, covering 2025-09-15 to 2025-11-20. Get the full timeline:

Most recent: Clinical Trial Update: Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer [Phase 2]